Proteomics Driven Approaches for Increased Stability
Time: 10:00 am
day: Conference Day Two
Details:
- Synlogic is a clinical-stage biotechnology company harnessing Escherichia coli Nissle as a livebiotherapeutic product (LBP) for delivery of therapies for under-served metabolic diseases such as phenylketonuria (PKU) and homocystinuria (HCU)
- We are assessing the use of various ‘-omics’ technologies as a tool to better understand manufacturing, stability and activity of our lyophilized LBP. In the present work, we aim to utilize mass spectrometry-based proteomics to assess the role of protein oxidation in product stability
- Insights have led to development of process-based changes and changes during varied fermentation batch processes which report nutrient limitation unnoticeable by typical fermentation sensors
